Updates are available Correction dated 2021-09-18

Article History

Received: 9 November 2020

Accepted: 18 May 2021

First Online: 7 August 2021

Change Date: 18 September 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10120-021-01248-8

Declarations

:

: E. Van Cutsem has received research funding (to his institution) from Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Ipsen, Lilly, Merck KGaA, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Roche, and Servier. He has also served in an advisory/consultancy role for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Incyte, Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Merck KGaA, Novartis, Roche, and Servier. M. Amonkar reports employment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. C. S. Fuchs served in an advisory/consultancy role for Agios, Amylin Pharmaceuticals, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, EvolveImmune Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics. He also serves as a director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. He is a cofounder of EvolveImmune Therapeutics and has equity in this private company. M. Alsina has received honoraria from Bristol Myers Squibb, Lilly, MSD, and Servier and served in an advisory/consultancy role for Bristol Myers Squibb, Lilly, MSD, and Servier. M. Özgüroğlu has received honoraria (personal and to his institution) from Astellas, Janssen, Novartis, Roche, and Sanofi; served in an advisory/consultancy role for Astellas, Janssen, and Sanofi; and received travel/accommodations from AstraZeneca, Bristol Myers Squibb, and Janssen. Y.-J. Bang served in an advisory/consultancy role for AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, Bristol Myers Squibb, Eli Lilly, Taiho, Daiichi-Sankyo, Astellas, BeiGene, GreenCross, Samyang Biopharm, Hanmi, and Genexine and received research grant/funding (to his institution) from MSD, AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Eli Lilly, Boehringer Ingelheim, MacroGenics, Boston Biomedical, FivePrime, Curis, Taiho, Takeda, Ono, Daiichi Sankyo, Astellas, BeiGene, Green Cross, CKD Pharma, and Genexine. H. C. Chung has received honoraria from Merck Serono, Lilly, Foundation Medicine; served in an advisory/consultancy role for Taiho, Celltrion, MSD, Lilly, Quintiles, Bristol Myers Squibb, Merck Serono, Gloria, BeiGene, Amgen, and Zymeworks; and received research grants/funding (to his institution) from Lilly, GlaxoSmithKline, MSD, Merck Serono, Bristol Myers Squibb/Ono, Taiho, Amgen, and BeiGene. K. Muro has received honoraria for speaking from Bristol Myers Squibb, Eli Lilly, Chugai Pharmaceutical, Takeda Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical Co., Ltd., and Sanofi; served in an advisory/consultancy role for AstraZeneca, Amgen, and Ono Pharmaceutical Co., Ltd; and received research funding (to his institution) from MSD, Daiichi Sankyo, Parexel International, Sumitomo Dainippon Pharma, Pfizer, Mediscience Planning, Solasia Pharma, and Sanofi. E. Goekkurt has served in an advisory/consultancy role for Bristol Myers Squibb, Lilly, Merck KGaA, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Roche, and Servier. A. Benson has served in an advisory/consultancy role for CN, Bristol Myers Squibb, Patient Resource (educational document review), Research to Practice, AVBCC, Harborside, Therabionic, Guardant, Merck (DMC), Terumo, Lexicon, ACCC, ECOG-ACRIN, Amgen, Imedex, Artemida Pharma, Intellisphere OncLiv, American College of Radiology, China National Medical Association 6^th Affiliated Sun Yat-Sen Hospital, Springer, Health Advances, Lexicon, Array (Pfizer), NCCN, and ACCC. W. Sun has received research grant/funding (personal and to his institution) from Merck. Z. A. Wainberg has served in an advisory/consultancy role for AstraZeneca, Bayer, Daiichi, Five Prime, Lilly, Merck, and Molecular Templates; received funding (to his institution) from AstraZeneca, Daiichi, Five Prime, Lilly, and Merck; and received travel/accommodations from Bayer, Daiichi, Lilly, Merck, and Molecular Templates. J. M. Norquist is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. X. Chen is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. C.-S. Shih is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. K. Shitara has received honoraria from AbbVie, Novartis, and Yakult; served in an advisory/consultancy role for Astellas Pharma, Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Taiho, MSD, Novartis, AbbVie, GlaxoSmithKline; and received research grants/funding (to his institution) from Lilly, Ono Pharmaceutical, Dainippon Sumitomo Pharma, MSD, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, and Mediscience.

: The study was conducted in accordance with the protocol and its amendments and with Good Clinical Practice guidelines.

: All patients provided written informed consent before enrollment.